Received: 1 July 2019
Accepted: 29 October 2019
First Online: 27 November 2019
Ethics approval and consent to participate
: SL, BF, ML and PFL are all involved in the design and conduct of clinical trials of novel therapeutic agents that utilise the change in SOFA score as a key endpoint. SL reports consultancy fees from Inotrem SA, during the conduct of the study and is the founding director of Critical Pressure Ltd., outside the submitted work. PFL reports personal fees from Inotrem, during the conduct of the study. ML reports non-financial support from Inotrem, during the conduct of the study. BF reports personal fees from Inotrem, during the conduct of the study, and personal fees from Biomérieux, Aridis, Ashai-Kasai, Polyphor, AM-Pharma and Ferring, outside the submitted work.
: SL is a founding director of critical pressure ltd, a biotechnology company developing novel vasopressors for the treatment of shock. He also receives consultancy fees from Inotrem SA Ltd. for his work developing novel therapeutics for septic shock.